Fibrinogen
Plasma Fibrinogen
What it is
Fibrinogen is a large soluble glycoprotein produced by the liver that plays two distinct roles in physiology: haemostasis and inflammation. In haemostasis, fibrinogen is the substrate for clot formation — when a blood vessel is damaged, the enzyme thrombin converts soluble fibrinogen into insoluble fibrin, which polymerises to form the structural mesh of a blood clot. Without adequate fibrinogen, clotting cannot occur; with excess fibrinogen, the blood is in a prothrombotic state. In inflammation, fibrinogen is an acute-phase reactant — its hepatic production is directly stimulated by IL-6 and other inflammatory cytokines. This makes fibrinogen a downstream marker of the same inflammatory cascade that produces hsCRP. Unlike hsCRP, which has no direct physiological role in cardiovascular pathology, fibrinogen participates mechanically in both thrombosis and atherosclerosis — elevated fibrinogen raises plasma viscosity, promotes platelet aggregation, and directly contributes to plaque formation and arterial thrombosis. It bridges the inflammatory and haemostatic domains of cardiovascular risk.
Why we measure it
A major meta-analysis by the Fibrinogen Studies Collaboration, published in JAMA (2005), pooled individual participant data from 154,211 adults across 31 prospective studies to examine the relationship between plasma fibrinogen and cardiovascular outcomes. After adjusting for age, sex, smoking, blood pressure, and lipid levels, the analysis found that each one standard deviation increase in fibrinogen was associated with a 1.8-fold increase in coronary heart disease risk and a 1.6-fold increase in stroke risk — effects comparable in magnitude to those of total cholesterol and blood pressure. Beyond its direct association with cardiovascular events, fibrinogen provides complementary information alongside hsCRP and IL-6. Individuals can have discordant elevations — fibrinogen elevated while hsCRP is normal, or vice versa — because they reflect slightly different aspects of the inflammatory and coagulation state. A protocol that measures all three captures a broader inflammatory burden than any single marker alone. Elevated fibrinogen in combination with elevated hsCRP is particularly associated with high thrombotic risk.
Why every 3 months
Fibrinogen responds to inflammatory stimuli, smoking cessation, physical activity, and dietary changes on a timescale of weeks to months — similar to hsCRP. Regular aerobic exercise and smoking cessation are among the most consistently effective interventions for reducing fibrinogen. As with other acute-phase reactants in the Pulse draw, the trend across quarters — stable, falling, or rising — provides more clinically meaningful information than any single point measurement.
What movement means
There is no single universally adopted clinical guideline defining diagnostic thresholds for fibrinogen comparable to the ADA's HbA1c classifications. The Fibrinogen Studies Collaboration used sex-specific thirds of the distribution in their analyses. Standard laboratory reference ranges for plasma fibrinogen in adults are typically between 2.0 and 4.0 g/L, with variation between assay methods and laboratories. The ranges below reflect commonly used clinical reference values and their associations with cardiovascular risk in the research literature — not a single authoritative diagnostic guideline.
Normal
2.0 – 4.0 g/L
Within the standard clinical laboratory reference range for adult plasma fibrinogen.
Standard laboratory reference ranges — vary by institution and assay method
Elevated
> 4.0 g/L
Above the upper standard reference limit. In the Fibrinogen Studies Collaboration meta-analysis, individuals in the upper third of the fibrinogen distribution had approximately 1.8-fold elevated coronary heart disease risk versus the lowest third.
Fibrinogen Studies Collaboration, JAMA, 2005 — doi:10.1001/jama.294.14.1799
In the protocol
References
- 1.
Fibrinogen Studies Collaboration. “Plasma Fibrinogen Level and the Risk of Major Cardiovascular Diseases and Nonvascular Mortality: An Individual Participant Meta-analysis.” JAMA. 2005.
- 2.
Danesh J, Collins R, Appleby P, Peto R. “Association of Fibrinogen, C-Reactive Protein, Albumin, or Leukocyte Count with Coronary Heart Disease: Meta-analyses of Prospective Studies.” JAMA. 1998.
- 3.
Emerging Risk Factors Collaboration. “C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction.” New England Journal of Medicine. 2012.
- 4.
Ernst E, Resch KL. “Fibrinogen as a Cardiovascular Risk Factor: A Meta-analysis and Review of the Literature.” Annals of Internal Medicine. 1993.